STERIS plc (NYSE:STE – Get Free Report) announced a quarterly dividend on Wednesday, October 30th,Zacks Dividends reports. Stockholders of record on Tuesday, November 19th will be paid a dividend of 0.57 per share by the medical equipment provider on Thursday, December 19th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date is Tuesday, November 19th.
STERIS has increased its dividend payment by an average of 8.7% per year over the last three years and has increased its dividend annually for the last 20 consecutive years. STERIS has a payout ratio of 22.6% meaning its dividend is sufficiently covered by earnings. Equities analysts expect STERIS to earn $9.93 per share next year, which means the company should continue to be able to cover its $2.28 annual dividend with an expected future payout ratio of 23.0%.
STERIS Trading Down 0.5 %
Shares of STE opened at $220.12 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. STERIS has a 1-year low of $195.47 and a 1-year high of $248.24. The company has a market capitalization of $21.73 billion, a P/E ratio of 50.26 and a beta of 0.85. The firm’s 50 day simple moving average is $230.37 and its 200 day simple moving average is $228.26.
Insider Activity at STERIS
In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares in the company, valued at approximately $10,603,710. The trade was a 35.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.14% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
STE has been the subject of a number of research reports. Stephens reiterated an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a report on Thursday, November 7th. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and increased their price target for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research note on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Finally, StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and an average target price of $253.00.
View Our Latest Research Report on STERIS
STERIS Company Profile
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
- Five stocks we like better than STERIS
- The Most Important Warren Buffett Stock for Investors: His Own
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- The How And Why of Investing in Oil Stocks
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- 3 Monster Growth Stocks to Buy Now
- Time to Load Up on Home Builders?
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.